BBNX Beta Bionics, Inc.
Legal ·
A purported stockholder sued Beta Bionics and certain executive officers in a California federal court in September. The company says a loss is not currently probable nor estimable.
A purported stockholder sued Beta Bionics and certain executive officers in federal court in California, alleging misstatements about iLet. The company says it intends to defend and that any loss is not currently probable or estimable.
Beta Bionics told the SEC that its initial public offering and a concurrent private placement brought in gross proceeds of $229.1 million before underwriting discounts and expenses. The company's own release puts its share of the IPO at about $212.1 million, well below the $234.6 million headline figure.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $100.3 million | $65.1 million |
| Research and development | $34.8 million | $26.2 million |
| Net income (loss) | -$73.2 million | -$54.8 million |
| Cash from operations | -$50.9 million | -$48.3 million |
| Cash and equivalents | $31.6 million | $30.4 million |
| Short-term investments | $187.5 million | $73.1 million |
Our latest story on this, dated Oct 27, 2026: "Beta Bionics discloses securities class action over iLet statements". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 31, 2025: "Beta Bionics closes IPO and $17.00 private placement for $229.1 million in gross proceeds". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jan 31, 2025: "Beta Bionics closes IPO and $17.00 private placement for $229.1 million in gross proceeds". The story links the filing or release it is based on. Read the story.
Beta Bionics, Inc. trades under the ticker BBNX on NASDAQ.
Beta Bionics, Inc. is listed on NASDAQ.
Our directory records Beta Bionics, Inc. under United States.
aibio.space lists Beta Bionics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
$100.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Beta Bionics, Inc. reported a net loss of $73.2 million for the fiscal year ended Dec 31, 2025, and used $50.9 million of cash in operations, per its annual report to the SEC.
$34.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$240.2 million in cash and short-term investments at Sep 30, 2026, per its 10-Q.
Our latest story on Beta Bionics, dated Oct 27, 2026: "Beta Bionics discloses securities class action over iLet statements". A purported stockholder sued Beta Bionics and certain executive officers in a California federal court in September. The company says a loss is not currently probable nor estimable. Source.
Press Follow on this page to add Beta Bionics to your Following list, or subscribe to the aibio.space newsletter. We have published 3 stories naming Beta Bionics so far, in Financings, Legal.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio